Inside The Altascientist: Unpacking the Bioanalytical and Regulatory Considerations for Antisense Oligonucleotide (ASO) Studies
Antisense oligonucleotides—or ASOs—are short, synthetic, single-stranded oligonucleotides extensively used for altering RNA expression to reduce, restore, or modify protein expression via several distinct mechanisms. With possible applications extending to both neurological and non-neurological conditions, there is great potential for valuable new therapeutics.
Developing robust bioanalytical assays is essential for accurately quantifying ASOs within intricate biological matrices, including eye, liver, or brain tissues, and these assays must exhibit high sensitivity to detect ASOs at low concentrations while simultaneously being immune to interference from other components in the sample. Hybridization-based assays have emerged as reliable and effective methods for precisely quantifying ASOs both in circulation and within targeted tissues.
In issue 12 of The Altascientist, we explore advances in hybridization-based assays more deeply, in addition to:
- regulatory considerations
- case studies
- bioanalytical considerations, including:
- ADAs and metabolite interference
- ASO quantitation in tissues
- method sensitivity
Listen to or read Issue 12 of The Altascientist on altasciences.com, or wherever you listen to podcasts to learn more:
WHAT IS THE ALTASCIENTIST?
The Altascientist is a scientific journal written by the scientific and research experts at Altasciences. In each issue, they share their decades of knowledge to help sponsors along their early-phase drug development journeys, as well as explore the latest challenges and innovations in the industry.
Explore the full collection of The Altascientist in our Resource Center, or listen to each issue on our audiobook library.
View the full library of The Altascientist publications.
Browse the full collection The Altascientist audiobooks.